The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients

Clinical Nephrology

Volumn 73, Issue 6, 2010, Pages 431-438

  Don, B R ^a   Kim, K ^a   Li, J ^a   Dwyer, T ^a   Alexander, F ^a   Kaysen, G A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Albumin; IL 6; Inflammation CRP; Prealbumin; sICAM; TNF ; VEGF

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; HUMAN ALBUMIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PLACEBO; PREALBUMIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOOT ULCER; HEMATURIA; HEMODIALYSIS; HUMAN; HYPOALBUMINEMIA; MALE; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 77952618631     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73431     Document Type: Article

References (27)

1. United States Renal Data System. 1995 Annual Data Report. Am J Kidney Dis. 1995; 26: 569-584.
2. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35: 469-476. (Pubitemid 30124077)
3. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi P, Palla R, Tetta C. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 1154-1160. (Pubitemid 38628135)
4. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998; 32: 107-114. (Pubitemid 28311878)
5. Chertow GM, Goldstein-Fuchs DJ, Lazarus JM, Kaysen GA. Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. Kidney Int. 2005; 68: 2794-2800. (Pubitemid 43251025)
6. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990; 15: 458-482.
7. Connors LH, Gertz MA, Skinner M, Cohen AS. Nephelometric measurement of human serum prealbumin and correlation with acute-phase proteins CRP and SAA: results in familial amyloid polyneuropathy. J Lab Clin Med. 1984; 104: 538-545. (Pubitemid 14015749)
8. Kaysen GA, Dubin JA, Müller HG, Rosales L, Levin NW, Mitch WE, HEMO Study Group NIDDK. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int. 2004; 65: 1408-1415. (Pubitemid 38406981)
9. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau et. al. Aproposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008; 73: 391-398.
10. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med.2005; 353: 238-248. (Pubitemid 41058323)
11. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM, Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007; 298: 1163-1170.
12. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130-1137. (Pubitemid 47609037)
13. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098. (Pubitemid 44749317)
14. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Understanding the pathophysiology of hemodialysis access problems as a prelude to developing innovative therapies. Nat Clin Pract Nephrol. 2008; 4: 628-638.
15. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol. 2004; 15: 538-548.
16. Rahmati MA, Homel P, Hoenich NA, Levin R, Kaysen GA, Levin NW. The role of improved water quality on inflammatory markers in patients undergoing regular dialysis. Int J Artif Organs. 2004; 27: 723-727. (Pubitemid 39369017)
17. Kaysen GA, Greene T, Daugirdas JT, Kimmel PL, Schulman GW, Toto RD, Levin NW, Yan G, HEMO Study Group. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis. 2003; 42: 1200-1211. (Pubitemid 37486764)
18. Kaysen GA, Dubin JA, Müller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int. 2000; 58: 346-352.
19. Goffe B, Cather JC. Etanercept: an overview. JAm Acad Dematol. 2003; 49: S105-S111.
20. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004; 350: 2167-2179.
21. Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum. 2003; 33: 1-18.
22. Sidak Z. Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association. 1967; 62: 626-633.
23. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008; 51: 2375-2384. (Pubitemid 351815163)
24. Kaysen GA, Kotanko P, Zhu F, Sarkar SR, Heymsfield SB, Kuhlmann MK, Levin NW. Estimation of adipose pools in hemodialysis patients. J Ren Nutr. 2008; 18: 473-478.
25. Winkler G, Kiss S, Keszthelyi L, Sápi Z, Ory I, Salamon F, Kovács M, Vargha P, Szekeres O, Speer G, Karádi I, Sikter M, Kaszás E, Dworak O, Gerö G, Cseh K. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol. 2003; 149: 129-135.
26. Kanaan N, Goffin E, Maisin D, Struyven J, Jadoul M. CRP measurement: does the assay matter in hemodialysis patients?. Clin Nephrol. 2008; 70: 503-507.
27. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. PEACE Investigators. Circulation. 2007; 115: 1528-1536.